Crossmark

Recombinant Activated Factor VIIa (rFVIIa) Treatment in Very-Low-Birth-Weight (VLBW) Premature Infants with Acute Pulmonary Hemorrhage: A Single-Center, Retrospective Study

Crossref DOI link: https://doi.org/10.1007/s40272-016-0203-3

Published Online: 2016-11-08

Published Print: 2017-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cosar, Hese

Isik, Halil

Cakır, Salih Cagrı

Yar, Nese

Goksen, Bulent

Tokbay, Hakan

Kertmen, Hasan

Erdoğan, Nihal

Durak, Ikbal
License Information

Text and Data Mining valid from 2016-11-08

Version of Record valid from 2016-11-08
More Information

Article History

First Online: 8 November 2016

Compliance with Ethical Standards

:

: None.

: Hese Cosar, Halil Isik, Salih Cagrı Cakır, Nese Yar, Bulent Goksen, Hakan Tokbay, Hasan Kertmen, Nihal Erdoğan, and Ikbal Durak declare no conflict of interest.

Document is current

Any future updates will be listed below